Blueprint Medicines Corp. (BPMC)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal.
The deal announced Monday is Sanofi's third of the year so far.
Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings
BMPC's first-quarter earnings and sales miss estimates. However, shares rally on raised Ayvakit sales guidance for 2025.
Blueprint Medicines Corporation (BPMC) Q1 2025 Earnings Call Transcript
Blueprint Medicines Corporation (NASDAQ:BPMC ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Jenna Cohen - Vice President, Investor Relations & Global Business Communications Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Becker Hewes - Chief Medical Officer Mike Landsittel - Chief Financial Officer Christy Rossi - Chief Operating Officer Conference Call Participants Marc Frahm - TD Cowen Laura Prendergast - Raymond James Michael Yee - Jefferies Colleen Kusy - Baird Derek Archila - Wells Fargo Brian Cheng - JPMorgan Reni Benjamin - Citizens Ami Fadia - Needham David Dai - UBS Judah Frommer - Morgan Stanley Sudan Loganathan - Stephens Operator Good morning. My name is Angela and I'll be your conference operator today.
Blueprint Medicines (BPMC) Reports Q1 Loss, Lags Revenue Estimates
Blueprint Medicines (BPMC) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $1.32 per share a year ago.
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?
Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Blueprint Medicines Continues Targeting Mast Cells For Potential Billion-Dollar Growth
Blueprint Medicines' focus on Ayvakit continues to pay off, which has ample untapped revenue potential in advanced and indolent systemic mastocytosis. Additionally, their pipeline includes other promising candidates (BLU-808 and Elenestinib) for mast cell disorders and genetically driven cancers. Their recent data seems to reinforce Ayvakit's long-term safety, efficacy, and potential bone health benefits in systemic mastocytosis patients.
BPMC Q4 Earnings and Sales Miss Estimates, Shares Decline
Blueprint Medicines' fourth-quarter earnings and sales miss estimates. Shares of the company decline following the announcement.
Blueprint Medicines Corporation (BPMC) Q4 2024 Earnings Call Transcript
Blueprint Medicines Corporation (NASDAQ:BPMC ) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Cassie Saitow - Director, Investor Relations Kate Haviland - President and Chief Executive Officer Philina Lee - Chief Commercial Officer Becker Hewes - Chief Medical Officer Mike Landsittel - Chief Financial Officer Christina Rossi - Chief Operating Officer Conference Call Participants Brad Canino - Stifel Salveen Richter - Goldman Sachs Michael Schmidt - Guggenheim Brian Cheng - J.P. Morgan Derek Archila - Wells Fargo Marc Frahm - TD Cowen Laura Prendergast - Raymond James Michael Ulz - Morgan Stanley David Dai - UBS Reni Benjamin - Citizens JMP Colleen Kusy - Baird Matthew Biegler - Oppenheimer David Nierengarten - Wedbush Securities Operator Good morning.
Blueprint Medicines (BPMC) Reports Q4 Loss, Misses Revenue Estimates
Blueprint Medicines (BPMC) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $1.82 per share a year ago.
Will Blueprint Medicines (BPMC) Report Negative Earnings Next Week? What You Should Know
Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Buy Blueprint Medicines (BPMC) After Golden Cross?
After reaching an important support level, Blueprint Medicines Corporation (BPMC) could be a good stock pick from a technical perspective. BPMC recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy
BPMC stock rallies 18% on the company's optimistic 2025 outlook encompassing Ayvakit sales growth and pipeline progress.
